Compare BTGO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTGO | TBPH |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | 603 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 961.8M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | BTGO | TBPH |
|---|---|---|
| Price | $10.37 | $16.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $14.83 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 511.3K | 473.9K |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $1.04 |
| Revenue Next Year | $34.97 | N/A |
| P/E Ratio | $10.81 | ★ $8.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.25 | $8.33 |
| 52 Week High | $15.30 | $21.03 |
| Indicator | BTGO | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 60.30 |
| Support Level | $9.82 | $13.41 |
| Resistance Level | $10.59 | $19.04 |
| Average True Range (ATR) | 0.74 | 0.51 |
| MACD | 0.32 | 0.20 |
| Stochastic Oscillator | 91.30 | 87.99 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.